- Home
- MPU vs CRIS Comparison
MPU vs CRIS Comparison
Compare MPU & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | CRIS |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 20.6M |
| IPO Year | 2023 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MPU | CRIS |
|---|---|---|
| Price | $0.33 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 8.2M | 481.4K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.21 | $0.36 |
| 52 Week High | $4.44 | $2.48 |
Technical Indicators
Market Signals| Indicator | MPU | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 29.09 |
| Support Level | $0.21 | N/A |
| Resistance Level | $0.75 | $0.57 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 19.30 | 1.03 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Corp is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.